Company news

Enlivex Ltd. news in 2022

Enlivex Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

December 4, 2022

Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies

November 27, 2022

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

November 14, 2022

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

September 11, 2022

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

September 5, 2022

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

August 23, 2022

Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update

August 21, 2022

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

August 16, 2022

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

August 2, 2022

Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

June 5, 2022

Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 30, 2022

Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

May 24, 2022

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

May 22, 2022

Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

May 4, 2022

Enlivex Announces Upcoming Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 1, 2022

Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates

April 28, 2022

Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells

March 7, 2022

Enlivex Strengthens Management Team with the Appointment of Biotech Industry Veteran Einat Galamidi, M.D., as Vice President, Medical

February 21, 2022

Decks in 2022